{
    "clinical_study": {
        "@rank": "97717", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Determine the toxicity of cyclophosphamide and rabbit anti-thymocyte\n      globulin in patients with diffuse systemic sclerosis.\n\n      II.  Determine the efficacy of this regimen in terms of controlling disease in these\n      patients."
        }, 
        "brief_title": "Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis", 
        "condition": "Systemic Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Scleroderma, Systemic", 
                "Scleroderma, Diffuse", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Patients receive cyclophosphamide IV over 1-2 hours on day 1 and rabbit\n      anti-thymocyte globulin IV over 6-8 hours on days 2-5.\n\n      Patients are followed on days 60-85 and then every 3 months for 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Diagnosis of diffuse systemic sclerosis\n\n        Progressive disease Skin score at least 16 Interstitial or pulmonary vasculitis (FVC or\n        DLCO no greater than 70% predicted) with evidence of alveolitis by bronchoalveolar lavage\n        (BAL) Proteinuria (more than 500 mg/24 hours) Rapid deterioration in pulmonary function\n        (at least 15% decrease in FVC or DLCO within the past 6 months) or new evidence of\n        alveolitis by CT scan changes or BAL\n\n        No acute renal failure secondary to systemic sclerosis crisis\n\n        DLCO greater than 20% predicted\n\n        Ineligible for or refused autologous or allogeneic peripheral blood stem cell or bone\n        marrow transplantation\n\n        --Prior/Concurrent Therapy--\n\n        Endocrine therapy: Concurrent prednisone allowed if prior chronic use\n\n        Other: At least 4 days since prior immunosuppressive therapy\n\n        --Patient Characteristics--\n\n        Performance status: Karnofsky 50-100%\n\n        Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least\n        100,000/mm3\n\n        Hepatic: Bilirubin less than 2.5 times upper limit of normal (ULN) SGOT less than 2.5\n        times ULN\n\n        Renal: See Disease Characteristics Creatinine clearance at least 35 mL/min No requirement\n        for renal dialysis\n\n        Cardiovascular: Ejection fraction greater than 45% No myocardial infarction within the\n        past 12 months No unstable angina No uncontrolled cardiac arrhythmias No evidence of\n        congestive heart failure\n\n        Pulmonary: See Disease Characteristics\n\n        Other:\n\n          -  Not pregnant\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  HIV negative\n\n          -  No active uncontrolled infection\n\n          -  No hypersensitivity to rabbit proteins\n\n          -  No prior hemorrhagic cystitis requiring transfusion\n\n          -  No concurrent active hemorrhagic cystitis by cystoscopy (if prior history)\n\n          -  No concurrent malignancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "20", 
        "firstreceived_date": "May 6, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00016458", 
            "org_study_id": "199/15818", 
            "secondary_id": "FHCRC-1473.00"
        }, 
        "intervention": [
            {
                "intervention_name": "anti-thymocyte globulin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antilymphocyte Serum", 
                "Cyclophosphamide"
            ]
        }, 
        "keyword": [
            "arthritis & connective tissue diseases", 
            "rare disease", 
            "systemic sclerosis"
        ], 
        "lastchanged_date": "September 2, 2008", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80262"
                    }, 
                    "name": "University of Colorado Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center", 
            "last_name": "Leona Holmberg", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Unspecified"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00016458"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fred Hutchinson Cancer Research Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2008"
    }, 
    "geocoordinates": {
        "Duke University Medical Center": "35.994 -78.899", 
        "Fred Hutchinson Cancer Research Center": "47.606 -122.332", 
        "University of Colorado Cancer Center": "39.739 -104.985"
    }
}